Colleen Devinney, DO
Family Medicine · Fort Washington, PANPI 1518923481
Payments from drug & device makers
Across 85 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$274
- Novo Nordisk$271
- AbbVie$180
- Pfizer$148
- AstraZeneca$145
- Sanofi Pasteur Inc.$112
- plus $631 from 19 others
What the payments were for
- Food & beverage$1,66294%
- Gifts$312%
- Other$684%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 12 | $274 |
| Novo Nordisk | 15 | $271 |
| AbbVie | 9 | $180 |
| Pfizer | 8 | $148 |
| AstraZeneca(2 entities) | 8 | $145 |
| Sanofi Pasteur Inc. | 6 | $112 |
| Welch Allyn | 2 | $99 |
| Dexcom, Inc. | 2 | $75 |
| Inspire Medical Systems, Inc. | 3 | $73 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Exact Sciences | 2 | $39 |
| GSK | 2 | $38 |
| Boston Scientific | 1 | $30 |
| Merck | 2 | $29 |
| Biogen | 1 | $26 |
| Astellas Pharma US Inc | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Abbott | 1 | $22 |
| Amgen | 1 | $21 |
| Shield Therapeutics Inc | 1 | $20 |
| Novartis | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Bausch Health US, LLC | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
How this compares
$1,761 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 42 | $52,339 |
| EliquisApixaban | 45 | $50,997 |
| OzempicSemaglutide | 26 | $45,108 |
| JardianceEmpagliflozin | 28 | $38,589 |
| XareltoRivaroxaban | 16 | $15,018 |
| MyrbetriqMirabegron | 11 | $9,939 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,262 |
| Atorvastatin Calcium | 286 | $3,991 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,819 |
| Nebivolol Hcl | 30 | $2,124 |
| Rosuvastatin Calcium | 99 | $1,883 |
| Levothyroxine Sodium | 142 | $1,711 |
| Metoprolol Succinate | 116 | $1,628 |
| Amlodipine Besylate | 209 | $1,546 |
| Duloxetine Hcl | 55 | $1,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $274 | $52,33942 claims |
| PfizerEliquis | $148 | $50,99745 claims |
| Novo NordiskOzempic | $271 | $45,10826 claims |
| Astellas Pharma US IncMyrbetriq | $25 | $9,93911 claims |
| AstraZenecaSymbicort | $145 | $4,26214 claims |
| GSKArnuity Ellipta | $38 | $2,81912 claims |
| AbbVieSynthroid | $180 | $94919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Fort Washington
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.